Sector
PharmaceuticalsOpen
₹5,130Prev. Close
₹5,133.65Turnover(Lac.)
₹4,896.19Day's High
₹5,243.95Day's Low
₹5,08752 Week's High
₹5,578.852 Week's Low
₹3,447Book Value
₹928.11Face Value
₹2Mkt Cap (₹ Cr.)
62,500.81P/E
34.14EPS
150.52Divi. Yield
0.7816 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
9 Feb 2024
12:00 AM
Dividend
Dividend Amount: 35
Record Date: 17 Feb, 2024
19 May 2023
12:00 AM
AGM
Announcement Date: 19 May, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 9,325.94 | 8,719.75 | 7,601.84 | 6,256.53 |
Net Worth | 9,349.85 | 8,743.66 | 7,625.75 | 6,280.44 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 8,829.81 | 7,219.68 | 6,677.08 | 5,300.26 |
yoy growth (%) | 22.3 | 8.12 | 25.97 | 16.53 |
Raw materials | -3,565.89 | -2,665.02 | -2,550.56 | -2,075.22 |
As % of sales | 40.38 | 36.91 | 38.19 | 39.15 |
Employee costs | -1,434.49 | -1,158.72 | -1,066.76 | -861.63 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,753.37 | 1,897.08 | 1,338.08 | 934.29 |
Depreciation | -218.98 | -198.93 | -186.84 | -107.65 |
Tax paid | -212.12 | -199.22 | -73.66 | -218.45 |
Working capital | 954.38 | 1,212.29 | 1,245.84 | 514.21 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.3 | 8.12 | 25.97 | 16.53 |
Op profit growth | -7.11 | 32.79 | 47.85 | 13.05 |
EBIT growth | -7.66 | 40.9 | 42.42 | 5.28 |
Net profit growth | -8.53 | 33.26 | 76.63 | -18.94 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 | 8,344.36 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 | 8,344.36 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 310.84 | 216.08 | 162.65 | 233.21 | 104.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Basudeo N Singh
Managing Director
SANDEEP SINGH
Executive Director
Mritunjay Kumar Singh
Non-Exec. & Independent Dir.
A K Purwar
Non-Exec. & Independent Dir.
SANGEETA KAPILJIT SINGH
Non-Exec. & Independent Dir.
SUDHA RAVI
Company Sec. & Compli. Officer
Manish Narang
Non-Exec. & Independent Dir.
Dheeraj Sharma
Non-Exec. & Independent Dir.
Narendra Aneja
Executive Director
SARVESH SINGH
Executive Director
Madhurima Singh
Independent Director
Sujjain Talwar
Executive Director
Srinivas Singh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Alkem Laboratories Ltd
Summary
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Ltd was incorporated as a private limited company on August 8, 1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of Company was changed to Alkem Laboratories Limited with effect from October 26, 1988.In 1978, the company established its first plant at Taloja Maharashtra. In 1992, the company established its manufacturing facility in Mandwa, Maharashtra, which was later converted into an API facility in 2005. In 2003, the company set up a research and development facility for ANDA development
Read More
What is the Alkem Laboratories Ltd share price today?
The Alkem Laboratories Ltd shares price on N/A is Rs.₹5221.9 today.
What is the Market Cap of Alkem Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alkem Laboratories Ltd is ₹62435.65 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Alkem Laboratories Ltd?
The PE and PB ratios of Alkem Laboratories Ltd is 34.14 and 5.82 as of 22 Jul ‘24
What is the 52 Week High and Low of Alkem Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Alkem Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alkem Laboratories Ltd is ₹3440.05 and ₹5581.2 as of 22 Jul ‘24
What is the CAGR of Alkem Laboratories Ltd?
Alkem Laboratories Ltd's CAGR for 5 Years at 23.37%, 3 Years at 14.23%, 1 Year at 41.33%, 6 Month at 3.51%, 3 Month at 11.49% and 1 Month at -0.92%.
What is the shareholding pattern of Alkem Laboratories Ltd?
The shareholding pattern of Alkem Laboratories Ltd is as follows:
Promoters - 56.38 %
Institutions - 27.27 %
Public - 16.36 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
